Therefore, effective IFN-based therapy for CHC reduces hepatic inflammation (39), which has been considered to minimize side effects including immune tolerance, induced by endogenous IFN, even though this complex process involves IFN/IL-1β interactions (40). The gene discussed is IFNA1; the disease is cryohydrocytosis.